Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene - PubMed (original) (raw)

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

D J Slamon et al. Science. 1987.

Abstract

The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.

PubMed Disclaimer

Similar articles

• neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.
  Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D. Andrulis IL, et al. J Clin Oncol. 1998 Apr;16(4):1340-9. doi: 10.1200/JCO.1998.16.4.1340. J Clin Oncol. 1998. PMID: 9552035
• The association of HER-2/neu amplification with breast cancer recurrence.
  Carr JA, Havstad S, Zarbo RJ, Divine G, Mackowiak P, Velanovich V. Carr JA, et al. Arch Surg. 2000 Dec;135(12):1469-74. doi: 10.1001/archsurg.135.12.1469. Arch Surg. 2000. PMID: 11115354
• HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
  Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C, Osborne MP. Tiwari RK, et al. Anticancer Res. 1992 Mar-Apr;12(2):419-25. Anticancer Res. 1992. PMID: 1349794
• Follow-up study of HER-2/neu amplification in primary breast cancer.
  Clark GM, McGuire WL. Clark GM, et al. Cancer Res. 1991 Feb 1;51(3):944-8. Cancer Res. 1991. PMID: 1988136 Review.
• The significance of oncogene amplification in primary breast cancer.
  Seshadri R, Matthews C, Dobrovic A, Horsfall DJ. Seshadri R, et al. Int J Cancer. 1989 Feb 15;43(2):270-2. doi: 10.1002/ijc.2910430218. Int J Cancer. 1989. PMID: 2563720 Review.

Cited by

• Selective targeting of oncogenic hotspot mutations of the HER2 extracellular domain.
  Bang I, Hattori T, Leloup N, Corrado A, Nyamaa A, Koide A, Geles K, Buck E, Koide S. Bang I, et al. Nat Chem Biol. 2024 Oct 22. doi: 10.1038/s41589-024-01751-w. Online ahead of print. Nat Chem Biol. 2024. PMID: 39438724
• The Immunohistochemical Expression of the Oestrogen Receptor (ER), HER-2/NEU and Cytokeratin 8/18 and 5/6 in Invasive Breast Carcinoma.
  Rattan B, Manjari M, Kahlon SK, Kalra N, Bhalla A, Paul S. Rattan B, et al. J Clin Diagn Res. 2012 Nov;6(9):1495-8. doi: 10.7860/JCDR/2012/4086.2542. J Clin Diagn Res. 2012. PMID: 23285439 Free PMC article.
• Metabolic alterations in mammary cancer prevention by withaferin A in a clinically relevant mouse model.
  Hahm ER, Lee J, Kim SH, Sehrawat A, Arlotti JA, Shiva SS, Bhargava R, Singh SV. Hahm ER, et al. J Natl Cancer Inst. 2013 Aug 7;105(15):1111-22. doi: 10.1093/jnci/djt153. Epub 2013 Jul 2. J Natl Cancer Inst. 2013. PMID: 23821767 Free PMC article.
• A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications.
  Marotta M, Chen X, Inoshita A, Stephens R, Budd GT, Crowe JP, Lyons J, Kondratova A, Tubbs R, Tanaka H. Marotta M, et al. Breast Cancer Res. 2012 Nov 26;14(6):R150. doi: 10.1186/bcr3362. Breast Cancer Res. 2012. PMID: 23181561 Free PMC article.
• PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma.
  Yokoyama D, Hisamori S, Deguchi Y, Nishigori T, Okabe H, Kanaya S, Manaka D, Kadokawa Y, Hata H, Minamiguchi S, Tsunoda S, Obama K, Sakai Y. Yokoyama D, et al. Sci Rep. 2021 Apr 27;11(1):9013. doi: 10.1038/s41598-021-88331-3. Sci Rep. 2021. PMID: 33907203 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal